

European Liver Patients Association

(EUR)	31/12/2021	31/12/2020
Assets		
Fixed assets	51 026,11	57 523,08
III. Tangible fixed assets	47 626,11	54 123,08
B. Plant, machinery and equipment	46 858,08	53 552,04
C. Furniture and vehicles	768,03	571,04
IV. Financial fixed assets	3 400,00	3 400,00
C. Other financial fixed assets	3 400,00	3 400,00
2. Amounts receivable and cash guarantees	3 400,00	3 400,00
Current assets	1 016 884,64	821 884,99
VII. Amounts receivable within one year	0,00	2 968,42
A. Trade debtors	0,00	2 968,42
IX. Cash at bank and in hand	1 006 730,93	791 425,71
X. Accruals and deferred income	10 153,71	27 490,86
Total assets	1 067 910,75	879 408,07
Equity and liabilities		
Equity	824 345,40	773 719,15
III. Reserves	103 552,00	103 552,00
A. Reserves not available	103 552,00	103 552,00
4. Other	103 552,00	103 552,00
IV. Accumulated profits (+)/ losses (-)	720 793,40	670 167,15
Amounts payable	243 565,35	105 688,92
IX. Amounts payable within one year	18 456,09	19 226,42
C. Trade debts	3 969,94	1 177,42
1. Suppliers	3 969,94	1 177,42
E. Taxes, remuneration and social security	14 486,15	18 049,00
1. Taxes	5 372,02	4 151,48
2. Remuneration and social security	9 114,13	13 897,52

X. Accruals and deferred income	225 109,26	86 462,50
Total liabilities	1 067 910,75	879 408,07
Profit and loss account		
I. Operating income	403 947,35	478 803,30
A. Turnover	403 947,35	478 731,30
D. Other operating income	0,00	72,00
II. Operating charges	365 384,43	294 902,18
A. Goods for resale, raw materials and consumables	201 899,00	168 774,32
1. Purchases	201 899,00	168 774,32
B. Services and other goods	82 260,17	48 247,56
C. Remunerations, social security costs and pensions	72 896,68	70 615,38
D. Amortisations of and other amounts written down on formation expenses, intangible and tangible fixed assets	7 275,97	7 264,92
G. Other operating charges	1 052,61	0,00
III. Operating profit/loss	38 562,92	183 901,12
IV. Financial income	18 587,10	3 957,33
B. Income from current assets	0,00	0,22
C. Other financial income	18 587,10	3 957,11
V. Financial charges	6 523,77	26 747,07
C. Other financial charges	6 523,77	26 747,07
VI. Profit/loss of the period before taxes	50 626,25	161 111,38
IX. Profit/loss of the period	50 626,25	161 111,38
X. Transfer from/to untaxed reserves	0,00	6 694,00

A. Transfer from untaxed reserves	0,00	6 694,00
XI. Profit/loss of the period available for appropriation	50 626,25	167 805,38
Appropriation account	0,00	0,00
A. Profit/loss to be appropriated	720 793,40	167 805,38
1. Profit/Loss of the period available for appropriation	50 626,25	167 805,38
2. Profits/loss of the preceding period brought forward	670 167,15	0,00
D. Profit/loss to be carried forward	720 793,40	167 805,38
1. Profit to be carried forward	-720 793,40	-167 805,38

REVENUE 2021

INDUSTRY related		
AstraZeneca	€ 35.000,00	7,87%
Alexion	€ 6.000,00	1,35%
BI	€ 37.900,00	8,52%
BMS	€ 25.000,00	5,62%
Boston Scientific	€ 5.000,00	1,12%
CymaBay	€ 8.500,00	1,91%
Gilead	€ 147.070,84	33,06%
IncentivaPharma	€ 6.000,00	1,35%
Intercept	€ 10.000,00	2,25%
IPSEN	€ 27.100,00	6,09%
Mirum	€ 12.940,00	2,91%
Norgine	€ 7.000,00	1,57%
Novartis	€ 9.433,96	2,12%
Novonordisk	€ 15.600,00	3,51%
Replicor	€ 5.970,00	1,34%
Roche	€ 30.900,00	6,95%
Sequana Medical	€ 5.000,00	1,12%
Terumo	€ 8.500,00	1,91%
NON INDUSTRY related		
EU PROJECTS		
A-Tango	€ 31.257,80	7,03%
Microb-Predict	€ 9.804,35	2,20%
MEMBERSHIP	€ 0,00	0,00%
OTHER	€ 938,12	0,21%
TOTAL	444.915,07 €	100,00%